Stocktoria
Carl Zeiss Meditec AG AFX.DE
Carl Zeiss Meditec AG (AFX.DE) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 2.17% (safety: safe). FY2025 revenue was €2.2B at a 6.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Healthcare · percentile among 79 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.214 |
| Retained earnings / assets | 0.463 |
| EBIT / assets | 0.066 |
| Equity / liabilities | 1.659 |
About Carl Zeiss Meditec AG
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company has a strategic collaboration with Envision Health Technologies Inc. to help advance glaucoma care through gamified virtual reality technology. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
FAQ
Is AFX.DE financially healthy?
Carl Zeiss Meditec AG's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does AFX.DE pay a dividend, and is it safe?
Yes. Carl Zeiss Meditec AG pays a dividend yielding about 2.17% with a 37.2% payout ratio, rated “safe” for safety.
How profitable is AFX.DE?
In FY2025, Carl Zeiss Meditec AG had a net margin of 6.3% and a return on equity of 6.7%.
Is AFX.DE overvalued or undervalued?
Carl Zeiss Meditec AG trades at about 17.2× trailing earnings — below its 10-year norm (10-year range 25.2×–37.2×, median 28.7×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for AFX.DE?
The average Wall-Street price target for Carl Zeiss Meditec AG is €30.05, about 8.6% above the recent price, from 15 analysts (consensus: hold).
Is AFX.DE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Carl Zeiss Meditec AG: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 17.2×, a dividend yield of 2.17%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · DE · as of 2025-09-30. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.